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Abstract 17 
Mitochondria are important regulators of cell death and cell survival. Mitochondrial Ca
2+
 18 
levels are critically involved in both of these processes. On the one hand, excessive 19 
mitochondrial Ca
2+
 leads to Ca
2+
-induced mitochondrial outer membrane permeabilization 20 
and thus apoptosis. On the other hand, mitochondria need Ca
2+
 in order to efficiently fuel the 21 
tricarboxylic acid cycle and maintain adequate mitochondrial bioenergetics. For obtaining this 22 
Ca
2+
, the mitochondria are largely dependent on close contact sites with the endoplasmic 23 
reticulum (ER), the so called mitochondria-associated membranes. There, the inositol 1,4,5-24 
trisphosphate receptor Ca
2+
-release channels are responsible for the Ca
2+
 release from the ER. 25 
It comes as no surprise that this Ca
2+
 release from the ER and the subsequent Ca
2+
 uptake at 26 
the mitochondria is finely regulated at both organelles. Cancer cells often modulate ER-Ca
2+
 27 
transfer to the mitochondria in order to promote cell survival and inhibit cell death. An 28 
important protein family in the regulation of these Ca
2+
 signals and the onset of cancer is the 29 
B-cell lymphoma 2 (Bcl-2) family. Increasing reports highlight the ability of this family of 30 
proteins to finely regulate Ca
2+
 transfer from ER to mitochondria both in healthy cells and in 31 
cancer. In this review, we focus on recent insights into the dynamic regulation of ER-32 
mitochondrial Ca
2+
 fluxes by Bcl-2-family members and how this impacts on cell survival, 33 
cell death and mitochondrial energy production. 34 
  35 
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Introduction 36 
Ca
2+
 signaling plays important roles in a vast amount of cell physiological processes [1]. In 37 
cancer cells, Ca
2+
 signaling is altered in order to promote mitochondrial bioenergetics, cell 38 
proliferation, migration and survival whilst inhibiting cell death [2-6]. The involvement of 39 
Ca
2+
 signaling in the development of cancer and consequently the potential of Ca
2+
 signaling 40 
as a target for treatment, is becoming increasingly apparent [5-11]. In cancer cells, proteins 41 
involved in Ca
2+
 signaling have been reported to have differential expression profiles 42 
compared to healthy cells [12-15]. In addition, an increasing number of proto-oncogenes and 43 
tumor suppressors impact Ca
2+
-signaling pathways by directly modulating intracellular Ca
2+
-44 
transport systems with critical functions in cell survival and cell death [16-19].  45 
An important Ca
2+
-signaling pathway involved in both cell death and cell survival is the 46 
transfer of Ca
2+
 from the endoplasmic reticulum (ER) to the mitochondria [20]. These Ca
2+
 47 
transfers occur at the so-called mitochondria-associated ER membranes (MAM), which are 48 
close contact sites between the ER and the mitochondria [21]. A continuous small Ca
2+
 49 
transfer to the mitochondria is necessary in order to maintain proper energy production [22]. 50 
This Ca
2+
 is required by several enzymes (like pyruvate dehydrogenase, isocitrate 51 
dehydrogenase and α-ketoglutarate) of the tricarboxylic acid (TCA), promoting NADH and 52 
ATP production [23]. Besides this, Ca2+ also modulated the ATP synthase complex V and 53 
the adenine nucleotide translocator [24]. In addition to this mitochondrial pathway, pro-54 
survival Ca
2+
 oscillations activate calcineurin, which in turn dephosphorylates the nuclear 55 
factor of activated T-cells (NFAT), conferring its translocation into the nucleus [25]. Here, 56 
NFAT triggers the transcription of genes involved in cell proliferation. In contrast, large Ca
2+
 57 
transfers from the ER to the mitochondria may result in both Ca
2+
-induced mitochondrial 58 
outer membrane permeabilization (MOMP) and opening of the mitochondrial permeability 59 
transition pore (mPTP), the latter is formed by dimers of the F0F1 ATP synthase [4,26,27]. In 60 
this process, Ca
2+
 overload in the mitochondria triggers cardiolipin oxidation, resulting in the 61 
disassembly of the respiratory chain complex 2 (also known as succinate Dehydrogenase) 62 
subsequently leading to excessive reactive oxygen species (ROS) production [28]. 63 
Mitochondrial produced ROS can open the mPTP, ultimately leading to MOMP. At the level 64 
of the ER, the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) [29] is an important 65 
intracellular Ca
2+
-release channel involved in these Ca
2+
 transfers, whereas at the 66 
mitochondria, the voltage dependent anion channel (VDAC) (at the outer mitochondrial 67 
membrane) [30] and the mitochondrial Ca
2+
 uniporter (MCU) (at the inner mitochondrial 68 
membrane) [31,32] are important for transporting Ca
2+
 into the mitochondrial matrix.  69 
 70 
The B-cell lymphoma 2 (Bcl-2)-protein family, consisting of both anti- and pro-apoptotic 71 
members, is critically involved in regulating cell death and survival [33-36]. Dysregulated 72 
expression and function of Bcl-2 proteins have been implicated in oncogenesis, but also 73 
represent an “Achilles heel” in cancer cells that can be exploited by the use of Bcl-2 inhibitors 74 
[37-39]. Anti-apoptotic Bcl-2 proteins (like Bcl-2, Bcl-XL and Mcl-1) have been extensively 75 
described to inhibit apoptosis by binding to the Bcl-2 homology (BH) 3 domains  of the pro-76 
apoptotic Bcl-2-family members (like Bax, Bak, Bim, Bid…) via their hydrophobic cleft 77 
formed by the BH1, BH2 and BH3 domains, thereby inhibiting cell death [40]. A  recently 78 
developed class of compounds, so-called BH3-mimetic drugs, [40-42] are able to compete 79 
with pro-apoptotic Bcl-2-family members for the hydrophobic cleft of the anti-apoptotic Bcl-80 
2-family members. Hence, BH3-mimetics alleviate the inhibition of Bax and Bak by the anti-81 
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apoptotic Bcl-2-family members, effectively killing cancer cells that are dependent on anti-82 
apoptotic Bcl-2 proteins for their survival. In addition to this, the BH4 domain of Bcl-2 also 83 
contributes to the interaction with Bax via a site that is distinct from Bax’s BH3-domain [43]. 84 
Moreover, the isolated BH4 domain, delivered as a stapled peptide, neutralized the pro-85 
apoptotic activity of Bim-derived BH3 pptides by restricting Bax conformational change[44].  86 
 87 
Besides this, anti-apoptotic Bcl-2 proteins are also known to regulate ER to mitochondrial 88 
Ca
2+
 signaling at both organelles and several Bcl-2-family members, including Bcl-2 and Bcl-89 
XL, are present in the MAMs [45,46] (Fig. 1). At the ER, anti-apoptotic Bcl-2, Bcl-XL and 90 
Mcl-1 promote pro-survival IP3R-mediated Ca
2+
 oscillations, enhancing cell proliferation and 91 
mitochondrial energy production [47-49]. Bcl-2 (and Bcl-XL at high concentrations) also 92 
inhibits excessive pro-apoptotic IP3R-mediated Ca
2+
 release [50-53], thereby preventing Ca
2+
-93 
induced MOMP. At the mitochondrial side of the MAMs, anti-apoptotic Bcl-2 and Bcl-XL 94 
proteins inhibit VDAC1-mediated Ca
2+
 uptake in the mitochondria [45,54,55]. However, also 95 
stimulatory roles of Bcl-2-family members on VDAC1-mediated mitochondrial Ca
2+
 transfer 96 
have been described, thereby maintaining adequate mitochondrial Ca
2+
 levels that promote 97 
survival and mitochondrial bioenergetics [56,57]. Besides IP3Rs and VDAC, anti-apoptotic 98 
Bcl-2-family members also regulate other members of the Ca
2+
 toolkit at different locations in 99 
the cell (extensively reviewed in [33]). Mcl-1 located at the inner mitochondrial membranes 100 
was also shown to be crucial for normal mitochondrial bioenergetics by regulating the 101 
assembly of the F1F0-ATP synthase oligomers [58]. Finally, the F0F1 ATP synthase also 102 
emerged as a target for anti-apoptotic Bcl-XL allowing the direct regulation of ATP 103 
production via Bcl-2-family members [59,60]. In this review, we will focus on recent insights 104 
into the dynamic regulation of ER-mitochondrial Ca
2+
 fluxes, the involvement of anti-105 
apoptotic Bcl-2-family members and how this impacts cell survival, cell death and 106 
mitochondrial energy production (Fig. 2); three important aspects of cancer development. 107 
 108 
ER side of the MAMs 109 
ER Ca
2+
 release is an important determinant for both cell survival by regulating mitochondrial 110 
bioenergetics and for cell death via promoting mPTP opening. In most cells, including cancer 111 
cells, the IP3R is an important intracellular Ca
2+
-release channel responsible for this Ca
2+
 112 
release from the ER. Cancer cells have developed several ways to modulate IP3R-mediated 113 
Ca
2+
 release, of which Bcl-2-dependent regulation is one. 114 
IP3Rs 115 
A continuous Ca
2+
 flow from the ER to the mitochondria is necessary in order to maintain 116 
normal energy production. At the ER, the IP3R is responsible for this Ca
2+
 release and is 117 
therefore present at the MAMs (Fig. 1). Inhibition of the IP3R and thus of this continuous 118 
Ca
2+
 transfer to the mitochondria was already shown to result in the induction of autophagy, 119 
thereby managing the decrease in mitochondrial energy production [22]. New findings 120 
emerged, showing that cancer cells are addicted to constitutive IP3R-driven Ca
2+
 transfer to 121 
the mitochondria [61,62]. Similarly to normal/non-tumorigenic cells, cancer cells increase 122 
their autophagic flux upon IP3R inhibition in order to cope with the loss of Ca
2+
 influx into the 123 
mitochondria and subsequent reduction in energy production. However, in normal cells, this 124 
increase in autophagy is accompanied by a decrease in the proliferation rate at the G1/S 125 
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checkpoint [63], addressing the decreased availability of mitochondrial substrates for 126 
biosynthetic pathways of nucleosides and other cellular building blocks. In this way, cells 127 
may survive until normal Ca
2+
 transfer to the mitochondria is restored. In cancer cells, this 128 
increase in autophagy is not accompanied by a reduction in cell proliferation, likely due to a 129 
loss of the link between the monitoring of the mitochondrial health and the G1/S checkpoint. 130 
As such, these malignant cells proceed through the cell cycle without the necessary pool of 131 
nucleosides, resulting in a mitotic catastrophe and necrotic cell death.   132 
Anti-apoptotic Bcl-2-family members have been shown to regulate the IP3R. Both inhibitory 133 
[50-52] and stimulatory [47,49] effects, largely dependent on the Bcl-2-family member 134 
involved [64,65] and the strength of IP3R activation [25,53], have been described. As such, it 135 
was reported that in T-cell models, Bcl-2 can suppress IP3R-mediated Ca
2+
 release generated 136 
by strong T-cell receptor stimulation, thereby preventing excessive Ca
2+
 transfer into the 137 
mitochondria. This interaction occurs via Bcl-2’s BH4 domain and a stretch of 20 amino acids 138 
in the central coupling domain of the IP3R [52,64]. Peptides derived from this amino acid 139 
stretch were able to disrupt IP3R/Bcl-2 complexes in several cell types and models, thereby 140 
augmenting cell death in response to apoptotic triggers that act through Ca
2+
 signaling[25,66]. 141 
In contrast, Bcl-2, Bcl-XL and Mcl-1 also sensitize the IP3R to low levels of IP3 in order to 142 
promote pro-survival Ca
2+
 oscillations, thereby feeding Ca
2+
 into the mitochondria to maintain 143 
normal mitochondrial bioenergetics [47-49]. The C-terminus of the IP3R and the hydrophobic 144 
cleft of the Bcl-2 proteins have been proposed as important molecular determinants for 145 
generating these Ca
2+
 oscillations [67]. Recently, this was further explored and elucidated for 146 
Bcl-XL [53]. Indeed, two BH3-like domains were identified in the C-terminal region of the 147 
IP3R. Bcl-XL bound to these BH3-like domains via its hydrophobic cleft, apparently with 148 
different affinities. Functionally, using nuclear patch clamp approaches, simultaneous binding 149 
of Bcl-XL proteins to both BH3-like domains was shown to increase the open probability of 150 
the IP3R in response to low levels of IP3. Similarly to Bcl-2, high Bcl-XL concentrations were 151 
also able to inhibit IP3R-mediated Ca
2+
 release in response to strong IP3R stimulation. 152 
Important for this inhibition were the interaction with both the BH3-like domain conferring 153 
the highest affinity towards Bcl-XL as well as the region in the coupling domain of the IP3R 154 
targeted by Bcl-2’s BH4 domain. Binding of Bcl-XL to the coupling domain appeared with 155 
much lower affinity than the binding to the C-terminal tail. Also, compared to Bcl-2, Bcl-XL 156 
binding to this domain was much less prominent, which is consistent with previous findings 157 
from our group [48]. This may indicate that moderate levels of Bcl-XL will most likely 158 
operate in IP3R-sensitizing modus and thus will promote Ca
2+
 oscillations, while high levels 159 
of Bcl-XL will be needed to operate in IP3R-inhibiting modus. Finally, binding of Bcl-XL 160 
proteins to both BH3-like domains is involved in maintaining cell viability and in protecting 161 
cells from stress inducers. These molecular results  substantiate the previously observed 162 
sensitization of the IP3R by Bcl-XL [67], resulting in pro-survival Ca
2+
 oscillations, and 163 
underscore the importance of this interaction for cell viability. 164 
 The role of Bcl-XL in modulating IP3R-mediated Ca
2+
 release in order to promote 165 
mitochondrial bioenergetics was recently further highlighted [68]. The authors showed that 166 
Bcl-XL interacts with IP3R3 at the MAMs, where it increased Ca
2+
 transfer into the 167 
mitochondria, thereby enhancing TCA cycling. Upon ER-stress induction, Bcl-XL 168 
translocated more to the MAMs where the subsequent facilitation of Ca
2+
 transfer to the 169 
mitochondria and thus increased energy production helped the cells cope with the induced ER 170 
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stress. This further highlights that Bcl-XL exerts its protective effects against stress inducers in 171 
large part via modulating Ca
2+
 signaling. 172 
 173 
Mitochondrial side of the MAMs 174 
Cancer cells are highly depend on the mitochondria for their energy production. For 175 
sustaining this energy production, adequate control of mitochondrial Ca
2+
 levels is important. 176 
Anti-apoptotic Bcl-2 proteins are known regulators of this mitochondrial Ca
2+
 influx, thereby 177 
regulating mitochondrial bioenergetics. In addition, the F0F1 ATP synthase has also been 178 
identified as a target for anti-apoptotic Bcl-2-family members, thereby directly linking them 179 
to the production of ATP [58-60]. 180 
 181 
VDAC 182 
The large conductance channel VDAC is located at the outer mitochondrial membranes [30]. 183 
At the MAMs, VDAC is physically linked to the IP3R via molecular tethers like the 184 
chaperone protein glucose-regulated protein 75, allowing efficient Ca
2+
 transfer from the ER 185 
into the mitochondria [69]. Close regulation of mitochondrial Ca
2+
 uptake via VDAC is 186 
critical for maintaining mitochondrial energy production. Anti-apoptotic Bcl-2-family 187 
members are known to modulate this mitochondrial Ca
2+
 transfer through interactions with 188 
VDAC. Both Bcl-2 and Bcl-XL have been reported to inhibit VDAC1-mediated Ca
2+
 uptake 189 
into the mitochondria, thereby protecting cells from Ca
2+
-induced MOMP [45,54,55,70]. For 190 
the BH4 domain of Bcl-XL, but not Bcl-2, was sufficient to bind to VDAC1 and to directly 191 
inhibit VDAC1 single-channel activity [45]. Although different regions of Bcl-2, Bcl-XL as 192 
well VDAC-1 seem to be involved in this interaction, both anti-apoptotic proteins have been 193 
reported to target the N-terminus of VDAC1. Introducing VDAC1’s N-terminal into cells was 194 
shown to inhibit both Bcl-2’s and Bcl-XL’s protection against apoptosis, illustrating that 195 
VDAC1 could be a target for anti-cancer drugs [54,70-72]. However, at the level of the BH4 196 
domains, the N-terminal peptide of VDAC1 could only counteract the inhibitory action of 197 
Bcl-XL, but not that of Bcl-2’s BH4 domain. The BH4 domain of Bcl-2 also suppressed 198 
agonist-induced mitochondrial Ca
2+
 uptake and staurosporin-induced cell death, but acted 199 
through inhibition of IP3Rs, since IP3R-derived peptides were able to alleviate the inhibitory 200 
effects of Bcl-2’s, but not those of Bcl-XL’s BH4 domain [45].  201 
Although the interaction of Bcl-XL with VDAC1 is well established, the impact of Bcl-XL on 202 
VDAC1’s functional properties may be dichotomous. Besides inhibiting VDAC1 [45,54], 203 
Bcl-XL has been reported to enhance VDAC1 activity. Bcl-XL knockout MEF cells displayed 204 
a reduced VDAC1-mediated Ca
2+
 uptake in the mitochondria compared to the wild-type MEF 205 
cells [56]. Similarly, N-terminal peptides derived from VDAC1 that disrupt Bcl-XL binding to 206 
VDAC1 could also antagonize mitochondrial Ca
2+
 uptake in wild-type MEF cells, while these 207 
peptides lacked any effect in Bcl-XL-deficient MEF cells. While differences in experimental 208 
conditions may underlie the seemingly contrasting observations, these results may indicate 209 
that Bcl-XL can have a dual impact on VDAC1’s Ca
2+
-flux properties dependent on VDAC1’s 210 
function as a pro-survival or pro-death protein. Hence, Bcl-XL could stimulate basal pro-211 
survival and inhibit excessive pro-apoptotic VDAC1-mediated mitochondrial Ca
2+
 transfer, 212 
thereby fine-tuning mitochondrial Ca
2+
 handling according to cellular needs, with respect to 213 
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cell fate decisions. The molecular basis for these opposite effects of Bcl-XL on VDAC1 214 
remains poorly understood.  215 
Mcl-1 has been shown to positively regulate VDAC in non-small cell lung carcinoma cells 216 
[57]. In these cancer cells, Mcl-1 interacted with VDAC, with a pronounced role for its N-217 
terminus, thereby increasing mitochondrial Ca
2+
 uptake, resulting in increased ROS 218 
production and cell migration. Disrupting the Mcl-1/VDAC interaction utilizing N-terminal 219 
VDAC derived peptides could inhibit ROS production and cell migration. The importance of 220 
Mcl-1 at the mitochondria was further underscored by a recent study concerning different 221 
Mcl-1 splice variants [73]. In this study, increasing the expression of the short pro-apoptotic 222 
Mcl-1 isoform resulted in increased mitochondrial fusion via a reduced Mcl-1 dependent 223 
recruitment of dynamin-related protein 1 to the mitochondria. This was accompanied by 224 
hyperpolarization of the mitochondrial potential and increased mitochondrial Ca
2+
 uptake, 225 
thereby increasing the susceptibility to apoptotic stimuli. Whether this increase in 226 
mitochondrial Ca
2+
 uptake was also mediated through the interaction with VDAC was not 227 
evaluated. Nevertheless, it would be interesting to assess whether the short pro-apoptotic Mcl-228 
1 isoform would shift VDAC-mediated mitochondrial Ca
2+
 uptake towards more pro-229 
apoptotic levels in comparison to the long pro-survival Mcl-1 isoform. 230 
 231 
F0F1 ATP synthase 232 
In cultured hippocampal neurons, Bcl-XL was shown to be present at the inner mitochondrial 233 
membranes, where it directly targets the β-subunit of the F0F1 ATP synthase [59,60]. This 234 
interaction stabilized the mitochondrial membrane potential via the closure of a membrane 235 
leak pathway. This increased the enzymatic activity of the F0F1 ATP synthase, thereby 236 
promoting ATP production during neural activity. In addition, the interaction seems to occur 237 
via Bcl-XL’s hydrophobic cleft, since ABT-737 could reverse the effects of Bcl-XL on the 238 
F0F1 ATP synthase. Recently, this process was further explored and was shown to be 239 
important for neuronal survival [74]. In response to excitotoxic stimuli, cyclin B1 and cyclin 240 
dependent kinase 1 (CdK1) accumulated in the mitochondria. There, the cyclin B1-Cdk1 241 
complex phosphorylates Bcl-XL, leading to its dissociation from the ATP-synthase. This leads 242 
to decreased ATP synthesis and the production of ROS species, resulting in the inhibition of 243 
respiratory chain complex I, mitochondrial dysfunction and potentially neuronal death.  244 
 245 
Potential therapeutic opportunities  246 
Promoting ER-mitochondrial Ca
2+
 transfer 247 
Many chemotherapeutics trigger intracellular Ca
2+
 release from the ER, causing, or at least 248 
contributing to, mitochondrial Ca
2+
 overload. This Ca
2+
 release is often considered as a non-249 
specific side effect of the drug, but in many cases it contributes to obtain maximal therapeutic 250 
effects [75]. Moreover, recent studies have unraveled the molecular mechanisms underlying 251 
the impact of chemotherapeutics and photodynamic therapy on intracellular Ca
2+
 homeostasis 252 
[18,76,77].  These anti-cancer regimens caused the accumulation of the tumor suppressor p53 253 
at the ER membranes, where it enhanced SERCA2b activity. These effects were independent 254 
of the transcriptional roles of p53. Recruitment of p53 at the ER augmented the Ca
2+
 filling 255 
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state of the ER stores, increasing the susceptibility to apoptotic stimuli and the likelihood for 256 
mitochondrial Ca
2+
 overload. Cells deficient in p53 did not display this effect and were 257 
resistant to chemotherapy. This resistance could be overcome by SERCA and/or MCU 258 
overexpression. 259 
Inhibiting ER-mitochondrial Ca
2+
 transfer 260 
The therapeutic potential of modulating intracellular Ca
2+
 signaling, more specifically the 261 
Ca
2+
 transfer from ER to mitochondria, in cancer is nicely illustrated by recent work of the 262 
group of Dr. Foskett [9,61]. They showed that inhibition of ER to mitochondrial Ca
2+
 transfer 263 
via IP3Rs in cancer cells, like in normal cells, results in the induction of autophagy. However, 264 
when this increase in autophagy is not accompanied by a halt in proliferation, these cells will 265 
die mainly through necrosis. This could prove to be a very specific way of eliminating cancer 266 
cells by effectively turning the increased proliferative capacity of cancer cells against 267 
themselves, whereas healthy cells can cope with this loss of Ca
2+
 transfer to the mitochondria. 268 
A major challenge here will be to specifically target the Ca
2+
 transfer into the mitochondria.  269 
Antagonizing anti-apoptotic Bcl-2 proteins 270 
A lot of effort is being made in developing BH3-mimetic drugs targeting the hydrophobic 271 
cleft of anti-apoptotic Bcl-2-family members. The first generation of BH3 mimetics (ABT-272 
737 and ABT-263) inhibited both Bcl-2 and Bcl-XL, resulting in severe side effects related to 273 
thrombocytopenia due to the dependence of thrombocytes on Bcl-XL for their survival 274 
[41,78]. More recently, a Bcl-2-selective BH3-mimetic inhibitor was developed, namely 275 
ABT-199/venetoclax, which is a very promising anti-cancer drug that has been approved for 276 
the treatment of chronic lymphocytic leukemia [79]. Whether these BH3-mimetic drugs also 277 
influence the ability of anti-apoptotic Bcl-2-family members to modulate intracellular Ca
2+
 278 
release is less well understood, although some studies reported this more recently. With the 279 
identification of the two BH3-like domains at the C-terminus of the IP3R, the ABT-737 280 
compound was shown to disrupt the binding of Bcl-XL to the C-terminus of the IP3R thereby 281 
abolishing both the stimulatory and inhibitory effects of Bcl-XL on IP3R-mediated Ca
2+
 282 
release [53]. However, the contribution of Ca
2+
 signaling to ABT-737-induced cell death 283 
requires further investigation, since ABT-737 could cause cell death in primary chronic 284 
lymphocytic leukemia cells without inducing elevations in intracellular [Ca
2+
] [80]. 285 
Besides a direct impact on IP3R/Bcl-XL complexes, ABT-737 has also been proposed to 286 
modulate the sensitivity of cancer cells to chemotherapy via a mechanism that involves 287 
remodeling of ER-mitochondrial contact sites [81]. As such, cisplatin-resistant ovarian cancer 288 
cells could be re-sensitized to cisplatin by ABT-737. This drug increased ER-mitochondrial 289 
contact sites, thereby increasing cisplatin-induced elevations in mitochondrial Ca
2+
. Besides 290 
increased ER-mitochondrial contact sites, ABT737, when co-applied with cisplatin in 291 
cholangiocarcinoma cells, has been shown to induce mitochondrial fragmentation and 292 
mitophagy, resulting in cell death, while cisplatin alone induced mitochondrial hyperfusion, 293 
potentially underlying cell death resistance [82]. The combined ABT737/cisplatin treatment 294 
led to a decrease in Mcl-1 and an increase in Bax. Interestingly, Mcl-1 has recently been 295 
shown to be implicated in controlling mitochondrial dynamics [73].  296 
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In contrast to Bcl-XL, the hydrophobic cleft of Bcl-2 appeared dispensable for IP3R 297 
modulation [83]. Hydrophobic cleft Bcl-2 mutants that failed to bind Bax/Bak remained 298 
capable to interact with and inhibit the IP3R. In contrast, efficient IP3R inhibition by anti-299 
apoptotic Bcl-2 critically depended on the presence of Bcl-2’s transmembrane domain. Bcl-2 300 
lacking its C-terminal transmembrane domain failed to inhibit IP3R-mediated Ca
2+
 release and 301 
to suppress Ca
2+
-dependent apoptosis in an in cellulo context. Consistent with this, IP3R/Bcl-302 
2-protein complexes and IP3R inhibition by Bcl-2 were resistant to ABT199/venetoclax 303 
treatment. Also, acute addition of ABT199/venetoclax to a variety of permeabilized and intact 304 
cell systems did neither trigger Ca
2+
 release by itself nor directly affected ER-located Ca
2+
-305 
uptake and –release systems. Related to this, ABT199/venetoclax-induced apoptosis in Bcl-2-306 
dependent cancer cells appeared to occur independently of intracellular Ca
2+
 overload [83,84] 307 
although, in same instances, inhibition of Bcl-2 by BH3 mimetics  resulted in a rapid 308 
impairment of mitochondrial oxidative phosphorylation [85]. Notably, over the years, it has 309 
also become clear that Bcl-2 inhibition via targeting its BH4 domain has potential as an 310 
effective anti-cancer treatment [38,86-88]. Targeting Bcl-2 via the BH4 domain using Bcl-311 
2/IP3 receptor Disrupter-2 (BIRD-2), a stabilized TAT-linked peptide containing the 20 amino 312 
acids that represent the Bcl-2 interaction motif of IP3Rs, triggers intracellular Ca
2+
 overload 313 
and apoptotic cell death in a variety of cancer cell models, including chronic lymphocytic 314 
leukemia [80], diffuse large B-cell lymphoma [89], multiple myeloma, follicular lymphoma 315 
[90] and small cell lung carcinoma [91]. This cell death could be suppressed by buffering 316 
intracellular Ca
2+
 and by inhibiting IP3R activity [80,89]. Very recently, a small molecule 317 
(BDA-366) that targets the BH4 domain of Bcl-2, which was effective in lung cancers and 318 
multiple myeloma, has been developed [92,93]. The mechanism involved a conformational 319 
switch in Bcl-2 that turned it from a pro-survival protein to a pro-death protein by exposing its 320 
BH3 domain. A decrease in Bcl-2 phosphorylation may contribute to this pro-apoptotic switch 321 
induced by BDA-366. BDA-366, too impaired IP3R/Bcl-2 complex formation and raised 322 
cytosolic Ca
2+
 levels, although further work is needed to determine the contribution of Ca
2+
 323 
signaling to BDA-366-induced cell death in cancer cells. 324 
Mcl-1 gene amplifications are frequently found in many types of cancer [94]. Very recently, a 325 
Mcl-1 inhibitor (S63845) targeting Mcl-1’s hydrophobic cleft has been developed [95]. This 326 
compound was shown to be very specific for Mcl-1, well-tolerated by animal models and 327 
efficient at triggering cell death in Mcl-1-dependent tumor cells. As the regulation of VDAC1 328 
by Mcl-1 also stimulates cancer cell migration [57], Mcl-1 inhibitors may not only be useful 329 
to eliminate Mcl-1-dependent cancers by provoking cell death but also by counteracting 330 
metastasis. However, at this point, it is not clear whether these Mcl-1 inhibitors can disrupt 331 
VDAC1/Mcl-1 complex formation.  332 
 333 
Conclusions 334 
Ca
2+
 transfer from ER to mitochondria is important for maintaining proper energy production, 335 
cell survival and cell death. The anti-apoptotic Bcl-2-family members regulate these Ca
2+
 336 
transfers at the level of the ER as well as of the mitochondria by directly targeting ER and 337 
mitochondrially located Ca
2+
-transport systems. Moreover, the molecular determinants 338 
underlying complex formation with these systems start to emerge, allowing to develop 339 
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strategies and tools to interfere with the Ca
2+
-signaling control functions of these Bcl-2 340 
proteins. These mechanisms also appear to be exploited by cancer cells to promote survival 341 
and mitochondrial bioenergetics, to contribute to cell death resistance and control metastasis. 342 
Thus, targeting the Ca
2+
-modulating abilities of these proteins may offer novel anti-cancer 343 
strategies. In addition to this, Ca
2+
 signaling might contribute to the cell death properties of 344 
recently developed Bcl-2 inhibitors, including BH3 mimetics and BH4-domain antagonists.  345 
 346 
  347 
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Figure legend 616 
 617 
Figure. 1. Bcl-2 and Bcl-XL and their targets in Ca
2+
 signaling, IP3R and VDAC1, are 618 
present in the MAMs. Representative immunoblots showing the presence of VDAC1, IP3Rs, 619 
Bcl-2, and Bcl-XL in the MAMs of MEFs. Calnexin (CNX) and cytochrome c (Cyt c) served 620 
as specific MAMs and mitochondrial markers, respectively. This research was originally 621 
published in Journal of Biological Chemistry with following reference: Monaco G, Decrock 622 
E, Arbel N, van Vliet AR, La Rovere RM, De Smedt H, Parys JB, Agostinis P, Leybaert L, 623 
Shoshan-Barmatz V, Bultynck G. The BH4 domain of anti-apoptotic Bcl-XL, but not that of 624 
the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of 625 
pro-apoptotic Ca
2+
 signals to mitochondria. Journal of Biological Chemistry; 290(14):9150-626 
61. © the American Society for Biochemistry and Molecular Biology. The original results 627 
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 630 
Figure. 2. Modulation of ER to mitochondrial Ca
2+
 transfers by anti-apoptotic Bcl-2 631 
proteins. ER to mitochondrial Ca
2+
 transfers are critical for the regulation of cell death and 632 
cell survival decisions. In order to fuel the TCA cycle, a continuous influx of Ca
2+
 into the 633 
mitochondria is required (green arrow), thereby promoting cell survival. Excessive 634 
mitochondrial Ca
2+
 uptake leads to Ca
2+
-induced MOMP and cell death (red arrow). The anti-635 
apoptotic side of the Bcl-2-protein family regulates these Ca
2+
 transfers at both organelles. 636 
During pro-survival Ca
2+
 signaling at the ER, Bcl-2, Bcl-XL and Mcl-1 modulate IP3R-637 
mediated Ca
2+
 release to generate Ca
2+
 oscillations. At the mitochondria Bcl-XL and Mcl-1 638 
can increase VDAC1-mediated Ca
2+
 uptake. Combining the effects at the two organelles 639 
results in an efficient and finely regulated Ca
2+
 uptake at the mitochondria which increases 640 
mitochondrial bioenergetics and promotes cell survival. In addition, Mcl-1 and Bcl-XL target 641 
the F0F1 ATP synthase, thereby regulating ATP-production. During pro-death signaling, Bcl-2 642 
and Bcl-XL can inhibit both pro-apoptotic Ca
2+
 release from the IP3R and the Ca
2+
 uptake into 643 
the mitochondria via VDAC. Finally, abolishing ER to mitochondrial Ca
2+
 transfers by either 644 
blocking IP3Rs or knocking down the MCU induces autophagy. When this is coupled to 645 
decreased cell proliferation (healthy cells) this increase in autophagy may rescue the cell. 646 
However, when proliferation is not halted (cancer cells) this results in cell death. 647 
Figure 1
ATP production/bioenergetics
Bcl-XL
Mcl-1
Bcl-2
Bcl-XL
Mcl-1
Bcl-2
Bcl-XL
Bcl-2
Bcl-XL
Autophagy 
inductionMcl-1
Bcl-XL
F0F1 ATP
synthase
MCU
VDAC
IP3R
Cell survival Cell death
IP3IP3
Ca2+Ca2+
Endoplasmic reticulum
Mitochondria
Figure 2
